Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 and AZD4205 in Advanced NSCLC with EGFR Mutations
NCT06295432Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Jun 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sunvozertinib, golixitinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
sunvozertinibgolixitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06295432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06295432.